Connor, Clark & Lunn Investment Management (CC&L)’s RAPT Therapeutics RAPT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-49,021	Closed	-$1.66M	–	1732
2025 Q4	$1.66M	Buy	+49,021	New	+$1.52M	﹤0.01%	971
2024 Q2	–	Sell	-1,843	Closed	-$132K	–	1637
2024 Q1	$132K	Buy	+1,843	New	+$256K	﹤0.01%	1446
2022 Q4	–	Sell	-1,177	Closed	-$226K	–	1390
2022 Q3	$226K	Buy	+1,177	New	+$223K	﹤0.01%	973

Connor, Clark & Lunn Investment Management (CC&L)'s RAPT Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 49,021 shares — an estimated $1.66M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RAPT in Q3 2022 and held it in 3 quarters. The position peaked at $1.66M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 49,021 RAPT Therapeutics shares in Q1 2026, an estimated $1.66M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RAPT Therapeutics in Q3 2022 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s RAPT Therapeutics position peaked at $1.66M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.